|
Reverse-phase protein microarray (RPPA) analysis of PD-L1 and growth factor receptor signal transduction pathways in hormone receptor (HR)-positive primary breast cancer tissue and correlation with relapse. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck; Novartis |
Consulting or Advisory Role - Merck; Novartis; Prometheus |
Research Funding - Prometheus |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Genentech/Roche (Inst); Lilly (Inst); Newlink Genetics (Inst) |
|
|
Consulting or Advisory Role - Genentech |
Research Funding - Genentech (Inst); Janssen (Inst); Tercica (Inst) |
|
|
Research Funding - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Theranostics Health |
|
|
Employment - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
Employment - Theranostics Health |
|
|
Honoraria - Amgen; Novartis |
Speakers' Bureau - Amgen; Novartis |
Research Funding - Novartis; Theranostics Health |
Expert Testimony - Amgen; Novartis |